CooperVision Highlights Myopia Management Breakthroughs at WCPOS V 2024
PorAinvest
lunes, 15 de julio de 2024, 2:04 am ET1 min de lectura
ECNS--
CooperVision's commitment to paediatric eye health was on full display at the event, showcasing the benefits of MiSight® 1 day – the first FDA-approved soft contact lens for myopia control in children. This groundbreaking innovation is part of CooperVision's portfolio of innovative contact lenses designed to improve the lives of their young patients [1].
Myopia, or nearsightedness, is a growing concern, particularly in children, with prevalence rates increasing globally. MiSight® 1 day's unique design helps slow the progression of myopia in children, which can significantly reduce the risk of developing more severe eye conditions later in life [2].
The three-day WCPOS V event served as a testament to CooperVision's role as a pioneer in myopia control solutions. With several educational sessions and scientific programs, CooperVision provided eye care practitioners (ECPs) with the latest evidence-based knowledge to improve their clinical care [1].
One of the key discussions centered around the Myopia Management Made Easy with MiSight® 1 day breakfast seminar, which provided ECPs with valuable insights into how to integrate this innovative solution into their practices [1]. Another session, Elevate Your Empirical Hybrid Fitting Game, explored the latest advances in hybrid contact lens fitting, which can be particularly beneficial for children with complex eye conditions [1].
In addition to these educational sessions, CooperVision also shared several scientific papers and posters at WCPOS V, further reinforcing their commitment to taking an evidence-based approach to care [1]. One such study explored trends in U.S. pediatric eye exams and contact lens prescribing, while another delved into the efficacy of MiSight® 1 day for children who exhibit slower and faster myopia progression [1].
As the world continues to grapple with the rising prevalence of myopia in children, CooperVision's commitment to innovative solutions and evidence-based care is more important than ever. Their pioneering work at WCPOS V serves as a shining example of their dedication to improving paediatric eye health.
References:
[1] CooperVision. (2024, January 15). CooperVision Leads Myopia Management and Specialty Lens Discussions at 2024 Global Specialty Lens Symposium. https://coopervision.com/our-company/news-center/press-release/coopervision-lead-myopia-management-and-specialty-lens
[2] American Academy of Ophthalmology. (2021, November 22). Myopia. https://www.aao.org/eye-health/diseases/myopia-nearsightedness
EDUC--
EYE--
At the 5th World Congress of Paediatric Ophthalmology and Strabismus (WCPOS V), CooperVision, a global myopia management leader, emphasized its dedication to paediatric eye health. As a Gold sponsor, they showcased the benefits of MiSight® 1 day, the first FDA-approved soft contact lens for myopia control in children. The three-day event gathered over 1,200 experts from around the world, reinforcing CooperVision's role in pioneering myopia control solutions.
In the world of ophthalmology, the 5th World Congress of Paediatric Ophthalmology and Strabismus (WCPOS V) was a beacon of knowledge, gathering over 1,200 experts from around the globe. Among the esteemed Gold sponsors was CooperVision, a global leader in myopia management [1].CooperVision's commitment to paediatric eye health was on full display at the event, showcasing the benefits of MiSight® 1 day – the first FDA-approved soft contact lens for myopia control in children. This groundbreaking innovation is part of CooperVision's portfolio of innovative contact lenses designed to improve the lives of their young patients [1].
Myopia, or nearsightedness, is a growing concern, particularly in children, with prevalence rates increasing globally. MiSight® 1 day's unique design helps slow the progression of myopia in children, which can significantly reduce the risk of developing more severe eye conditions later in life [2].
The three-day WCPOS V event served as a testament to CooperVision's role as a pioneer in myopia control solutions. With several educational sessions and scientific programs, CooperVision provided eye care practitioners (ECPs) with the latest evidence-based knowledge to improve their clinical care [1].
One of the key discussions centered around the Myopia Management Made Easy with MiSight® 1 day breakfast seminar, which provided ECPs with valuable insights into how to integrate this innovative solution into their practices [1]. Another session, Elevate Your Empirical Hybrid Fitting Game, explored the latest advances in hybrid contact lens fitting, which can be particularly beneficial for children with complex eye conditions [1].
In addition to these educational sessions, CooperVision also shared several scientific papers and posters at WCPOS V, further reinforcing their commitment to taking an evidence-based approach to care [1]. One such study explored trends in U.S. pediatric eye exams and contact lens prescribing, while another delved into the efficacy of MiSight® 1 day for children who exhibit slower and faster myopia progression [1].
As the world continues to grapple with the rising prevalence of myopia in children, CooperVision's commitment to innovative solutions and evidence-based care is more important than ever. Their pioneering work at WCPOS V serves as a shining example of their dedication to improving paediatric eye health.
References:
[1] CooperVision. (2024, January 15). CooperVision Leads Myopia Management and Specialty Lens Discussions at 2024 Global Specialty Lens Symposium. https://coopervision.com/our-company/news-center/press-release/coopervision-lead-myopia-management-and-specialty-lens
[2] American Academy of Ophthalmology. (2021, November 22). Myopia. https://www.aao.org/eye-health/diseases/myopia-nearsightedness

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios